Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 18:01:30 Source:sportViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Cruise worker 'murders newborn son on board ship': Shocked co
Next:Russian theater director and playwright go on trial over a play authorities say justifies terrorism
You may also like
- Celebrity birthdays for the week of May 26
- Putin calls Moscow terrorist attack bloody, barbaric, vows retribution
- Outbound travel boom mirrors China's consumption vibrancy
- Pirates add Paul Skenes to their roster ahead of his major league debut
- Investigators return to Long Island home of Gilgo Beach serial killing suspect
- 8 people were killed in a shooting attack at a bar in Ecuador, local police say
- Brentford beats Bournemouth on Yoane Wissa's stoppage
- Experts say gun alone doesn't justify deadly force in fatal shooting of Florida airman
- Pentagon vows to keep weapons moving to Ukraine as Kyiv faces a renewed assault by Russia